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782Objective: Numerous studies have shown that, when using conventional perfusion methodology, patients un-
dergoing coronary artery bypass grafting within 7 days of receiving clopidogrel are at increased risk of bleeding,
re-exploration, and blood transfusion. The purpose of this study was to evaluate the effect of clopidogrel admin-
istration before coronary artery bypass grafting on patients using thromboresistant surfaces with low-dose hep-
arin during surgical intervention.
Methods: Patients who underwent isolated coronary artery bypass grafting between 2005 and 2009 were incor-
porated in this retrospective study. Of these, 52 (22.2%) received clopidogrel within 5 days before the operation,
and 182 (77.8%) did not. Regression models determined the effect of clopidogrel on the rate of chest re-
exploration because of bleeding, 24-hour chest tube output, perioperative blood product transfusion, length
of stay, morbidity, and perioperative mortality. Hemorrhage-related preoperative risk factors, as well as those
found to be significant in univariate models, were included in the multivariate model.
Results: Chest tube drainage was significantly increased during the first 24 hours after the operation in the clo-
pidogrel group (679.7  305.8 vs 516.6  209.8 mL, P ¼ .0007). The need for intraoperative blood product
transfusion was similar; nevertheless, more patients receiving clopidogrel required fresh frozen plasma postop-
eratively (7.7% vs 1.1%, P ¼ .0232). However, risk-adjusted logistic regression showed that exposure to clo-
pidogrel was not a predictor of intraoperative or postoperative blood product transfusion. Lengths of stay in the
intensive care unit and hospital were shorter in patients receiving clopidogrel.
Conclusions: Hemostatic complications related to clopidogrel exposure within 5 days before an isolated coro-
nary artery bypass grafting operation can be alleviated by the application of a biocompatible perfusion strategy
using low-dose heparin in conjunction with a closed thromboresistant circuit. (J Thorac Cardiovasc Surg
2011;141:782-8)Platelets play a critical role in the pathophysiology of athero-
sclerosis, thrombus formation, and hemostasis. Tremendous
efforts were directed toward platelet inhibition to prevent
their participation in the propagation of arterial ischemic
diseases. Novel antiplatelet therapies implemented over the
last 2 decades have positively affected the clinical outcome
in patients with coronary artery disease.1 Randomized
controlled trials have demonstrated the advantages of clopi-
dogrel therapy in reducing the risk of myocardial infarction
(MI), ischemic stroke, and vascular death in patients
with recent MI, stroke, or established peripheral arterye Department of Cardiothoracic Surgery,a VA Boston Healthcare System; De-
ent of Cardiothoracic Surgery,b Brigham andWomen’s Hospital; Department
rdiothoracic Surgery,c Harvard Medical School; and Department of Cardio-
ic Surgery,d Mount Auburn Hospital, Boston, Mass.
res: Authors have nothing to disclose with regard to commercial support.
d for publication April 12, 2010; revisions received July 2, 2010; accepted for
ation Sept 10, 2010; available ahead of print Dec 13, 2010.
for reprints: Vladimir Birjiniuk, MD, MA, Department of Surgery, Cardio-
ic Surgery Division, Mount Auburn Hospital, 300 Mount Auburn St, Cam-
e, MA 02132 (E-mail: vbirjini@mah.harvard.edu).
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2010.09.002
The Journal of Thoracic and Cardiovascular Surgdisease (CAPRIE trial).2-5 Consequently, clopidogrel ad-
ministration has become a standard treatment in the
majority of patients with acute coronary syndrome (ACS)
admitted to the emergency department. However, more
patients are undergoing cardiopulmonary bypass (CPB)
surgery while receiving clopidogrel, either because of
comorbidities requiring additional treatment or as a rescue
procedure after percutaneous coronary stenting. Many
studies have evaluated the relationship between pre-
operative exposure to clopidogrel and consequent health
outcomes.6-12 The consensus among these studies is that
exposure to clopidogrel 7 days before surgical intervention
increases perioperative hemostasis-related complications,
as shown by (1) increased intraoperative and postoperative
nonsurgical bleeding and subsequent need for allogeneic
blood product transfusion and chest re-exploration, (2) in-
creased morbidity, and (3) increased length of hospital stay.
This has lead to increased use of resources, which further
burdens the health care system. Therefore theAmerican Col-
lege of Cardiology recommends that, when feasible, clopi-
dogrel treatment should be withheld 5 to 7 days before
surgical coronary revascularization.ery c March 2011
Abbreviations and Acronyms
ACS ¼ acute coronary syndrome
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
FFP ¼ fresh frozen plasma
MI ¼ myocardial infarction
pRBC ¼ packed red blood cell
OR ¼ odds ratio
Hussaini et al Perioperative Management
P
MIt is possible that, in addition to the clopidogrel treatment,
the major contributor to the cause of these complications
might be the use of conventional perfusion methodology
with nonthromboresistant circuits and high-dose heparin
during surgical intervention. This study elucidates a modi-
fied (unconventional) perfusion strategy that uses thrombor-
esistant surfaces in conjunction with low-dose heparin,
closed perfusion systems, normothermia, and maintenance
of high hematocrit values during CPB in an effort to help
alleviate the problems associated with clopidogrel therapy.
We present evidence in clopidogrel-exposed patients who
underwent isolated coronary artery bypass grafting
(CABG) at our institution.
MATERIALS AND METHODS
Study Groups and Patient Population
A prospective deidentified dataset from patients who underwent cardiac
surgery between 2005 and 2009 was obtained from the data management
office. Data were collected as per specifications of the Society of Thoracic
Surgeons National Data Registry. Our institutional policy does not require
institutional review board approval for the use of a completely deidentified
dataset. The study population consisted of 234 patients who underwent an
isolated on-pump CABG operation using our modified perfusion strategy.
Of these, 52 (22.2%) patients, who made up the exposure group, were ei-
ther receiving a 75 mg/d oral maintenance dose of clopidogrel or received
a 300-mg loading dose followed by the maintenance dose within 5 days be-
fore the operation, and the rest of the patients (182 [77.8%]), who consti-
tute the control group, were off clopidogrel within 5 days before the
operation. Patients in both groups were receiving aspirin (325 mg) before
the procedure. Patients who underwent off-pump CABG or had other car-
diac or vascular surgical procedures were excluded from the study. Simi-
larly, patients who received platelet glycoprotein IIb/IIIa inhibitors
within 24 hours, warfarin, or any other thrombolytic within 5 days before
their operations were excluded from the study. All surgical procedures
were performed by the same experienced cardiothoracic surgeon.
Perfusion Strategy Used During CABG Operations
Covalently bonded, heparin-coated, closed CPB circuits (Carmeda;
Medtronic, Minneapolis, Minn) in conjunction with low-dose heparin
were used in all patients. A Heparin Management System (Medtronic)
that uses kaolin as an activating agent was used to assess the degree of anti-
coagulation required to achieve and maintain a target activated clotting
time of 250 seconds or greater. A double-stage venous cannula, directional
arterial cannula, and collapsible, soft-shell venous reservoir (Medtronic)
were used to minimize air-to-blood interface and avoid stagnation of stored
blood in the circuit. All surfaces were coated with heparin, except for theThe Journal of Thoracic and Cacentrifugal pump. An arterial-to-venous shunt line distal to the arterial filter
allowed for recirculation of blood and crystalloid siphoning after bypass
routing. Cardiotomy suction was avoided to eliminate pump suckers and
the cardiotomy reservoir from the circuit. All field suction was instead di-
rected to a cell saver device (Haemonetics Corp, Braintree, Mass). Process-
ing of collected shed blood in the cell saver machine included 2 steps. It
was centrifuged to separate blood cells from plasma and other elements
picked up from the surgical field, and then it was washed with normal saline
(1000 mL) to remove all the plasma protein fractions, plasma water, plate-
lets, leukocytes, free hemoglobin, heparin, and embolic debris. The pel-
leted red blood cells were resuspended in normal saline solution to
a hematocrit value of approximately 60% and then retransfused into the pa-
tient. Pressure monitoring at the proximal and distal inlets of the membrane
oxygenator allowed for evaluation of pressure changes, which are indica-
tive of early emboli formation in the oxygenator. Pump prime volume
was kept at 1000 mL or less. To minimize hemodilution, perfusion lines
were kept short, and the crystalloid prime was replaced (Retro Autologus
Priming, RAP Prime Technique) by means of retrograde filling of the cir-
cuit with the patient’s blood while carefully monitoring the patient’s hemo-
dynamic status. Pulsatile flow was implemented during the period of aortic
crossclamping. Active systemic cooling was not performed, and the pa-
tient’s core temperature was maintained at 35C or greater. The aortic
root was vented by means of gravity to the venous reservoir. The initial
50 to 60mL of stagnant blood in the arterial linewas discarded into the field
before delivering blood through the aortic root. At the end of bypass, a Hep-
arinManagement System heparin–protamine titration assay was used to as-
sess the circulating heparin level and to determine the precise dose of
protamine necessary for heparin neutralization. A slow wean from bypass
was performed once the patient was completely rewarmed to 37C. After
decannulation, circuit blood was kept in constant motion to prevent stagna-
tion and clot formation.Perioperative Patient Care Policy
All patients were managed by the same cardiac surgery team following
a uniform patient care policy. Aminocaproic acid (Amicar; Xanodyne Phar-
maceuticals, Inc, Newport, Ky) and aprotinin were not part of our CPB pro-
tocol. Cerebral oximetric results were monitored routinely with the INOVS
device (Somanetics Corp, Troy, Mich); adjunctive transpump and trans-
cerebral Doppler scans were regularly used to monitor any embolic event.
Cerebral perfusion pressure was maintained at greater than 50 mm Hg dur-
ing the operation to avoid cerebral hypoperfusion. The patient’s own blood
cells shed during the operation were processed in the cell saver and trans-
fused immediately after termination of CPB. The hematocrit value was
maintained at 25% or greater during CPB and at greater than 30% during
the first 24 hours postoperatively in all patients. Intraoperative nonsurgical
bleeding after CPB termination, heparin neutralization, and normalization
of activated clotting time to the baseline value were managed by using me-
ticulous examination of all surgical fields, transfusion of the patient’s blood
cells from the cell saver, and, if required, autologous packed red blood cells
(pRBCs). Postoperative pRBCs were normally transfused if the hematocrit
value was less than 27% for patients aged 65 years and less or if the hemat-
ocrit valuewas less than 30% in those older than 65 years. Chest tube drain-
age was recorded on hourly basis and at the end of 24 hours and was
considered the primary measure of postoperative bleeding.Study Outcomes
The study’s end points were diagnosis of excessive perioperative non-
surgical bleeding stipulated by chest re-exploration, need for blood product
transfusion, length of stay, morbidity, and perioperative mortality. Postop-
erative bleeding was evaluated based on chest tube output; chest re-
exploration caused by hemorrhage was indicated when chest tube output
exceeded 500 mL in the first hour, 400 mL/h in the first 2 hours, 300
mL/h in the first 3 hours, or 200 mL/h for the first 4 hours.rdiovascular Surgery c Volume 141, Number 3 783
TABLE 1. Patients’ demographic and preoperative characteristics
Variable
Control
group
(n ¼ 182)
Clopidogrel
group
(n ¼ 52) P value
Age (y) 67.8  10.4 62.9  13.1 .0053
Sex
Female 54 (29.7) 15 (28.9) .9085
Male 128 (70.3) 37 (71.1) .9083
Weight (kg) 83.5  18.6 80.7  13.2 .3152
Race
White 165 (90.7) 44 (88) .7077
Black 6 (3.3) 2 (4.0) .6922
Other 11 (6.0) 4 (8.0) .3990
Diabetes 74 (40.7) 15 (28.9) .1217
Hypertension 164 (90.1) 40 (76.9) .0121
Congestive heart failure 30 (16.5) 4 (8.0) .1761
Chronic lung disease
No 128 (70.3) 40 (76.9) .6265
Mild 25 (13.7) 6 (11.5) .4223
Moderate 19 (10.5) 1 (2) .0612
Severe 10 (5.5) 5 (9.6) .1444
LV ejection fraction category 0.6822*
>45% 131 (72) 40 (76.9)
30%–45% 35 (19.2) 7 (13.5)
<30% 16 (8.8) 5 (9.6)
History of MI 97 (53.3) 33 (63.5) .1933
History of CHF 30 (16.5) 4 (7.7) .1126
History of CVA 30 (16.5) 7 (13.5) .5984
History of PVD 27 (14.8) 7 (13.5) .8042
History of arrhythmia 21 (11.5) 4 (7.7) .4285
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The term perioperative nonsurgical bleeding refers to any generalized
systemic bleeding manifested by an oozing surgical surface that is the re-
sult of abnormal hemostasis and is not corrected by surgical intervention.
Perioperative mortality was defined as any death within 30 days after sur-
gical intervention. All other variables were as defined by the Society of
Thoracic Surgeons’ adult cardiac data specifications.
Statistical Analysis
Data are expressed as percentages or means  standard deviations. Pa-
tients receiving clopidogrel preoperatively (clopidogrel group) were com-
pared with those who did not receive clopidogrel within 5 days before the
operation (control group). Preoperative, intraoperative, and postoperative
variables were compared between the 2 groups by using Student’s t test
for continuous variables and the c2 test or, where appropriate, Fisher’s ex-
act test for binary variables. The Cochran–Armitage test was used to com-
pare the ordinal categorical variables. Multivariate risk-adjusted logistic
regression models were constructed to determine the relationship between
exposure to clopidogrel and the need for each outcome of interest (chest re-
exploration caused by bleeding, blood product transfusion intraoperatively
and postoperatively, and operative mortality). All historic potential con-
founders and those variables with P values of less than .2 in the univariate
analyses were entered into a forward stepwise procedure. The risk factors
and potential confounders included age, weight, female sex, race, preoper-
ative hematocrit value, hemodialysis, renal failure, ejection fraction, num-
ber of new grafts, redo CABG, history of hypertension, diabetes, MI, and
urgency status. Model-fit analysis was evaluated based on the Hosmer–Le-
meshow guidelines. The c statistic was reported as an estimate of the dis-
criminative value of predictive models. Statistical significant was accepted
at the 95% confidence level (P<.05). All analyses were performed with
SAS statistical software (version 9.1; SAS Institute, Inc, Cary, NC).
The authors had full access to the data and take full responsibility for its
integrity. All authors have read and agreed to the manuscript as written.Cardiogenic shock at
the time of operation
2 (1.1) 1 (2.0) .5312
Preoperative hematocrit (%) 38.2  5.03 37.2  5.14 .1115
Preoperative creatinine (mg/dL) 1.1  0.5 1.0  0.3 .2457
Redo CABG 5 (2.7) 0.0 .1567
Operative status
Elective 46 (25.3) 6 (11.5) .0023
Urgent 132 (72.5) 43 (82.7) .0397
Emergency 4 (2.2) 3 (5.8) .1520
Prior cardiovascular intervention 36 (19.8) 18 (34.6) .0251
Preoperative IABP 14 (7.7) 5 (9.6) .6543
Data are presented as numbers (percentages) or as means  standard deviations. MI,
Myocardial infarction; CHF, congestive heart failure;CVA, cerebrovascular accident;
PVD, peripheral vascular disease; CABG, coronary artery bypass grafting; IABP,
intra-aortic balloon pump. *Cochran–Armitage test for trend.RESULTS
Patients’ Characteristics and Preoperative Risk
Factors
Comparable baseline characteristics were observed in
sex, weight, and race between the 2 groups (Table 1). A sta-
tistically significantly younger population was noted in the
clopidogrel group (62.9  13.1 vs. 67.8  10.4 years,
P ¼ .0053), who underwent more cardiovascular interven-
tions before their operations than the control group
(34.6% vs 19.8%, P¼ .0251). A higher but not statistically
significant proportion of the clopidogrel group had a history
of MI than in the control group (63.5% vs 53.3%,
P¼ .1933), and fewer patients had histories of hypertension
than in the control group (76.9% vs 90.1%, P ¼ .0121,
Table 1).Perioperative Characteristics and Outcomes
The perioperative parameters and clinical outcomes are
shown in Table 2. Compared with the control group, more
patients had their bilateral thoracic arteries used simulta-
neously for revascularization in the clopidogrel group
(25.0% vs 15.4%, P ¼ .0214), but there was no significant
difference in the total number of new grafts performed or
crossclamp or CPB times between the 2 groups. Two pa-784 The Journal of Thoracic and Cardiovascular Surgtients were given diagnoses of stroke postoperatively in
the clopidogrel group, whereas no patients had this adverse
event in the control group (3.8% vs 0.0%, P ¼ .0211). Pa-
tients premedicated with clopidogrel exhibited lower he-
matocrit (31.0%  5.4% vs 33.5%  2.4%, P ¼ .0020)
and creatinine (1.2  0.43 vs 1.4  0.95 mg/dL,
P ¼ .0215) values in the first blood test performed on post-
operative day 1 compared with those who did not receive
clopidogrel. As expected, the majority of the surgical proce-
dures were performed on an urgent status in the group re-
ceiving clopidogrel (82.7% vs 72.5%, P ¼ .0397).ery c March 2011
TABLE 2. Patients’ perioperative characteristics and 30-day
outcomes
Variable
Control
group
(n ¼ 182)
Clopidogrel
group
(n ¼ 52) P value
Total no. of CABG grafts 3.1  0.8 2.9  0.74 .3335
Arterial grafts 1.1  0.5 1.2  0.4 .0223
Venous grafts 1.9  0.7 1.7  0.7 .0291
Arterial graft type:
LITA 140 (76.9) 39 (75.0) .1044
LITA and RITA 28 (15.4) 13 (25.0) .0214
Crossclamp time (min) 62.8  22.1 59.2  22.1 .3149
Total bypass time (min) 85.6  26.5 81.3  24.8 .2858
Postoperative hematocrit (%) 33.5  2.4 31.0  5.4 .0020
Postoperative creatinine (mg/dL) 1.4  0.95 1.2  0.43 .0215
Length of stay (d)
Intensive care unit 2.6  2.3 2.4  2.04 .7008
Hospital 7.5  6.4 6.5  5.1 .2975
Incidence of postoperative
complications
Readmission to ICU 3 (1.7) 2 (3.9) .3338
Myocardial infarction 1 (0.5) 0 (0) 1.000
Postoperative stroke 0 (0) 2 (3.8) .0211
Postoperative pneumonia 0 (0) 0 (0)
Postoperative renal failure 3 (1.65) 0 (0) .9524
Postoperative sternal infection 1 (0.5) 0 (0) 1.000
Postoperative leg wound infection 4 (2.2) 1 (1.9) 1.000
Readmission within
30 day postoperatively
10 (5.5) 1 (1.9) .4635
Perioperative mortality 2.0 (1.1%) 0.0 (0%) .9007
Data are presented as numbers (percentages) or as means  standard deviations.
CABG, Coronary artery bypass grafting; LITA, left internal thoracic artery; RITA,
right internal thoracic artery; ICU, intensive care unit.
TABLE 3. Hemostasis-related manifestations
Variable
Control
group
(n ¼ 182)
Clopidogrel
group
(n ¼ 52) P value
Hemorrhage indicators
Re-exploration caused
by bleeding (%)
0.0 (0) 1 (1.9) .2222
Chest drainage in the
first 24 h (mL)
516.6  209.8 679.7  305.8 .0007
Allogeneic blood product
transfusion
Intraoperative
Received any type
of blood products
50 (27.5) 15 (28.9) .8454
Packed red blood cells 50 (27.5) 14 (26.9) .9375
Fresh frozen plasma 0 (0) 1 (1.9) .2222
Platelets 0 (0) 0 (0)
Cryoprecipitate 0 (0) 0 (0)
Within 24 h postoperatively
Received any type
of blood product
94 (51.7) 34 (65.4) .0793
Packed red blood cells 93 (51.1) 29 (55.8) .1682
Fresh frozen plasma 2 (1.1) 4 (7.7) .0232
Platelets 0 (0) 1 (1.9) .2222
Cryoprecipitate 0 (0) 0 (0)
Data are presented as numbers (percentages) or means  standard deviations.
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Postoperative chest tube drainage within the first 24
hours. Compared with the control group, patients who
were treated with clopidogrel within 5 days before their
CABG operations demonstrated, on average, higher chest
tube output during the first 24 hours postoperatively, and
this difference was statistically significant (679.7  305.8
vs 516.6  209.8 mL, P ¼ .0007, Table 3).
Re-exploration caused by bleeding. None of the patients
in the control group underwent chest re-exploration after
the initial operation. In contrast, 1 patient from the clopi-
dogrel group had to undergo chest re-exploration because
of bleeding. Surgical exploration revealed a significant
amount of fresh blood, as well as multiple clots, in the me-
diastinum and the pleural spaces bilaterally, without an
identifiable source of bleeding (Table 3).
Allogeneic blood product transfusion requirement.
Intraoperatively. Platelets or cryoprecipitate was not trans-
fused intraoperatively to any patient in any of the study
groups. The unadjusted univariate analysis revealed that
compared with the control group, the rate of pRBC transfu-
sion in the clopidogrel group was actually lower, although
the difference was not statistically significant (26.9% vsThe Journal of Thoracic and Ca27.5%, P ¼ .9375). No patients in the control group re-
ceived fresh frozen plasma (FFP); however, 2 units were
transfused to a patient in the clopidogrel group (0.0% vs
1.9%, P ¼ .2222, Table 3).
Within 24 hours postoperatively. The unadjusted univariate
analysis demonstrated a higher rate of pRBC (55.8% vs
51.1%, P ¼ .1682) and FFP (7.7% vs 1.1%, P ¼ .0232)
transfusion among the patients who received clopidogrel
compared with those who did not, and the need for FFP
was statistically significant. Multivariate risk-adjusted lo-
gistic regression analysis revealed that exposure to clopi-
dogrel does not predict the need for pRBC transfusion
intraoperatively, and the likelihood of receiving postopera-
tive blood transfusion is increased 1.6-fold (95% confi-
dence interval [CI], 0.8–3.3; P ¼ .2272), although this is
not statistically significant (Table 4).
Length of stay and resource use. The average length of
stay in the intensive care unit was not statistically signifi-
cant between the 2 groups (2.4  2.04 vs 2.6  2.3 days,
P ¼ .7008). Surprisingly, compared with the control sub-
jects, the clopidogrel-exposed patients left the hospital, on
average, 1 day earlier, but this difference was not statisti-
cally significant (6.5  5.1 vs 7.5  6.4 days, P ¼ .2975,
Table 2).
Perioperative mortality. There was no mortality observed
during the operations or within 30 days postoperatively in
the clopidogrel group, whereas 2 deaths were reported in
the control subjects after hospital discharge (Table 2).rdiovascular Surgery c Volume 141, Number 3 785
TABLE 4. Predictors of intraoperative and postoperative blood transfusion: Risk-adjusted multivariate analysis
Outcome Predictors Adjusted odds ratio 95% Confidence interval P value
Intraoperative blood product transfusion
Received any blood product* Clopidogrel 0.9 0.3–2.93 .8295
Female sex 6.04 2.2–16.7 .0005
Weight 0.96 0.93–0.99 .0102
Preoperative hematocrit 0.7 0.6–0.8 <.0001
Preoperative renal failure 3.7 1.3–10.2 .0139
Urgent CABG 5.3 1.4–19.8 .0130
No previous MI 0.4 0.1–1.1 .0715
Received pRBCsy Clopidogrel 0.7 0.2–2.6 .5722
Female sex 6.2 2.2–17.6 .0007
Weight 0.95 0.92–0.98 .0043
Preoperative hematocrit 0.64 0.54–0.8 <.0001
Preoperative renal failure 4.33 1.53–12.3 .0059
Urgent CABG 3.5 0.91–13.6 .0691
Postoperative blood product transfusion
Received any blood productsz Clopidogrel 1.6 0.8–3.3 .2272
Weight 0.98 0.96–1.00 .0541
Preoperative hematocrit 0.82 0.8–0.9 <.0001
No previous MI 0.51 0.3–0.94 .0307
Received any pRBCsx Clopidogrel 1.6 0.8–3.4 .2022
Weight 0.99 0.96–1.0 .0486
Preoperative hematocrit 0.8 0.8–0.9 <.0001
No previous MI 0.5 0.3–0.9 .0203
CABG, Coronary artery bypass grafting; MI, myocardial infarction; pRBC, packed red blood cell. *Hosmer and Lemeshow goodness-of-fit test: c2 ¼ 4.8, df ¼ 8, P ¼ .7804, c
statistic ¼ 0.95. yHosmer and Lemeshow goodness-of-fit test: c2 ¼ 2.4, df ¼ 8, P ¼ .7804, c statistic ¼ 0.96. zHosmer and Lemeshow goodness-of-fit test: c2 ¼ 7.30, df ¼ 8,
P ¼ .5073, c statistic ¼ 0.79. xHosmer and Lemeshow goodness-of-fit test: c2 ¼ 9.3, df ¼ 8, P ¼ .5073, c statistic ¼ 0.80.
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Clopidogrel is extensively used at various stages during
the management of coronary artery disease because of
its beneficial antiplatelet effect. An increased bleeding ten-
dency with subsequent requirement for allogeneic blood
transfusion during and after CABG surgery, as well
as increased risk of hemostatic reoperation in patients
treated with clopidogrel preoperatively, has been widely re-
ported.6-12 Nonsurgical bleeding diathesis during and after
an on-pump CABG operation is multifactorial. In addition
to the patients’ characteristics and medications, other im-
portant factors that are inherent in the surgical process
should be considered very important potential contributors.
The CPB circuit, anticoagulation regimen, systemic tem-
perature during CPB, status of the perfusion system that de-
fines the intraoperative blood-scavenging technique, and
hemodilution have been recognized as significant elements
altering blood components and ultimately increasing bleed-
ing propensity during and after CAGB surgery.13 The com-
mon denominator among all published data reporting on
the effect of clopidogrel exposure prior to an on-pump
CABG is the use of nonthromboresistant CPB with
a high-anticoagulation regimen. We hypothesized that
thromboresistant bypass circuits along with our modified
perfusion strategy might alleviate the perioperative
hemostasis-related consequences of clopidogrel treatment
before isolated on-pump CABG.786 The Journal of Thoracic and Cardiovascular SurgIn our study patients’ characteristics and intraoperative
variables were comparable between the 2 groups (Table
1). The younger age observed in the patients receiving clo-
pidogrel could be related to the recent trend in the manage-
ment of patients with ACS presenting to the emergency
department and the fact that the majority of this study pop-
ulation underwent CABG on an urgent basis (Tables 1 and
2). The younger age might explain the low rate of diabetes
and hypertension and the lower incidence of heart failure in
the clopidogrel group, whereas the higher rate of urgency is
in keeping with the higher rates of MI and the increased
trend toward angioplasty in this group compared with the
control group.
The postoperative increase in chest tube output (30%)
among clopidogrel-treated patients is consistent with what
has been reported in the literature6-8; however, one has to
consider that 100% of our study population was receiving
aspirin, and hemostasis-enhancing medications, such as
aminocaproic acid or aprotinin, were not used. In retrospect,
we probably expanded potential oozing surfaces by using
both internal thoracic arteries significantly more in patients
receiving clopidogrel than in the control group (Table 2),
which likely contributed to increased chest tube output.
This study showed no significant difference in chest
re-exploration between groups, and no predictors of
re-exploration were yielded in the multivariate analysis.
One (1.9%) patient receiving clopidogrel requiredery c March 2011
Hussaini et al Perioperative Managementre-exploration, which is far less than what has been reported
in the literature (Figure 1, A). However, our result is in
agreement with the low rate reported by others.9,14
Our major findings revolve around 3 outcomes.
First, platelets were not transfused intraoperatively, and
only 1 clopidogrel-treated patient received 2 units of
platelets in the postoperative period. Contrary to other re-
ports,6-8,10,11,15 this study demonstrated no statistically
significant difference in unadjusted pRBC transfusions bet-
ween the study groups intraoperatively or postoperatively.
The multivariate risk-adjusted analysis clearly revealed
that clopidogrel does not predict the need for intraoperative
blood product transfusion (odds ratio [OR], 0.9; 95% CI,
0.3–2.9; P ¼ .8295) in general or for pRBCs (OR, 0.7;
95%CI, 0.2–2.6; P¼ .5722) in particular, with similar find-
ings during the postoperative period (OR, 1.6; 95%CI, 0.8–
3.3; P ¼ .2272; Table 4). None of our patients in either
group received cryoprecipitate preoperatively. Other stud-
ies have also reported that patients receiving clopidogrel
did not require extra transfusion or have major bleeding;FIGURE 1. Selected outcomes comparison between the current study and
published data. A, Re-exploration caused by bleeding. B, Length of stay
(LOS). ICU, Intensive care unit. Asterisks denote the perfusion strategies
applied (* ¼ conventional, ** ¼ modified). Data are expressed as
means  standard errors or as percentages.
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Mhowever, aprotinin was routinely administered during surgi-
cal interventions in both of these studies.16,17 In contrast,
aprotinin was not part of our patient management, and
therefore the effect we have seen in our study is more
likely due to the collective result of our modified
perfusion strategy.
We have previously demonstrated that platelet dysfunc-
tion associated with CPB is a reversible phenomenon that
is exacerbated by systemic hypothermia and high-dose hep-
arin.13 It is well known that blood coagulation reactions are
temperature dependent, and therefore having systemic nor-
mothermia during bypass in this study might have facili-
tated normal hemostasis. Postoperative nonsurgical blood
loss is in part due to the release of larger platelets into the
circulation, which suggests that hyperfibrinolysis and com-
plement activation might play an important role in CPB-
induced platelet dysfunction.13 Using a thromboresistant
circuit, such as a heparin-bonded circuit, which is known
to activate the complement to a lesser degree than a conven-
tional nonthromboresistant circuit, would consequently
reduce the CPB-related platelet alteration. We have previ-
ously shown that, compared with conventional perfusion
methods, complete application of our modified perfusion
strategy significantly reduced the need for postoperative
platelets and pRBCs by 95% and 32%, respectively.18,19
Second, this study revealed no difference in length of stay
in either the intensive care unit or the hospital between the
2 groups. In fact, patients receiving clopidogrel were dis-
charged, on average, 1 day earlier than control subjects. Al-
though the intensive care unit stay is in agreement with what
has been reported,5,11,12,15 the overall hospital stay was 3 to
5 days shorter in our patients receiving clopidogrel than in
those studies (Figure 1, B). It has been shown that blood
product transfusion in post–cardiac surgery patients is an in-
dependent risk factor for postoperative infection and subse-
quently longer length of stay.20 The relatively short hospital
course observed in this study might be related to the lower
rates of blood product transfusion and the lack of postoper-
ative complications.
The third major finding of this study was the lack of peri-
operative mortality in the clopidogrel group. Although the
experience of the surgical team might have contributed to
this outcome, shorter hospital stay, less allogeneic blood
transfusion, and exceptionally rare hemostatic reoperation
might have also influenced such a positive outcome.
Because of the benefit of clopidogrel, it might potentially
follow in the footsteps of aspirin, with all patients undergo-
ing CABG receiving clopidogrel preoperatively. However,
delaying surgical revascularization to wash out the effect
of clopidogrel might increase the risk of MI while waiting
for surgical intervention by 1%.1 Therefore in light of these
facts and to minimize perioperative bleeding in patients un-
dergoing CABG while receiving clopidogrel, cardiac sur-
geons should focus on the modified elements of therdiovascular Surgery c Volume 141, Number 3 787
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Mperfusion strategy and adapt more physiologically relevant
perfusion methods that help balance the effect of passive
platelets accrued from the clopidogrel therapy.
In summary, this study reports for the first time the advan-
tages of using thromboresistant surfaces in conjunction with
low-dose heparin and a modified perfusion strategy in the
prevention of clopidogrel-mediated perioperative hemo-
static complications in patients undergoing isolated
CABG. It presents an alternative to postponing the surgical
procedure for such patients and thus evades the possibly
risky consequences of such a delay.
Although this study examined the exposure to clopidog-
rel within 5 days rather 7 days as in most published data, our
results were drawn from a small sample size, a single sur-
geon, and 1 institution. Therefore these results cannot be
linearly extrapolated to the general population. Although
logistic regression analysis was applied to adjust for all po-
tential confounding factors, bias in such a retrospective
study is always an important element that needs to be con-
sidered. Stratifying the groups by age and female sex would
have beenmore informative; however, the small sample size
would not permit suchmatching. As far as we know, 4 large-
volume centers in the United States used a similar perfusion
strategy in an isolated CABG surgery. Therefore evaluating
a larger database from all these centers as a component of
a multicenter study is warranted to further evaluate the pos-
itive effect of this perfusion methodology on the lack of
hemostasis-related complications resulting from pre-
CABG antiplatelet therapy.
We thank Andrew Gardner for his help in retrieving the data.References
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